Showing results (681-690 of 790) with videos related to

Sort By:
Pageof 79
Clinical and Translational Allergy|May 5, 2021
A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticariaViktoria Puhl, Hanna Bonnekoh, Jörg Scheffel, et al.
Journal of Hepatology|December 8, 2006
Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infectionEckart Schott, Heiko Witt, Holger Hinrichsen, et al.
The Journal of Biological Chemistry|June 22, 1999
M3 muscarinic acetylcholine receptors regulate cytoplasmic myosin by a process involving RhoA and requiring conventional protein kinase C isoformsD Strassheim, L G May, K A Varker, et al.
Nanomedicine (London, England)|April 6, 2012
Nanowires precisely grown on the ends of microwire electrodes permit the recording of intracellular action potentials within deeper neural structuresJohn E Ferguson, Christopher Boldt, Joshua G Puhl, et al.
Diabetes|November 5, 2014
Global biochemical profiling identifies β-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humansSheng Zhang, Songyan Wang, Matthew D Puhl, et al.
Journal of Medicinal Chemistry|January 10, 2019
Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity AnalysisChunfang Gu, Michael A Stashko, Ana C Puhl-Rubio, et al.
The Science of the Total Environment|December 10, 2023
Semi-continuous hydrothermal processing of pine sawdust for integrated production of fuels precursors and platform chemicalsBruna A Puhl, Crisleine P Draszewski, Francisco D Vezaro, et al.
The International Journal of Artificial Organs|July 16, 2002
A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver supportA Mundt, G Puhl, A Müller, et al.
Gynecologic Oncology|January 29, 2008
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancerE Steiner, K Pollow, D Hasenclever, et al.
Metabolism: Clinical and Experimental|May 14, 2025
Evaluation of tetrahydropyridazine-based peripherally restricted dual inhibitors of CB1R and inducible nitric oxide synthase (iNOS) for treating metabolic syndrome disordersPinaki Bhattacharjee, Szabolcs Dvorácskó, Océane Pointeau, et al.
Pageof 79